To me it does not come down to BioCryst being listed in the US and BTA not. BioCryst's management has done a far, far better job of marketing peramivir Vs GSK/BTA's relenza
Since Sept 1 BioCryst has:
Given 6 presentations available on their BioCryst's website.
Made 8 announcements regarding peramivir
Vs
0 presentations (at least none released to shareholders)
1 announcement regarding royalties.
No announcements from BTA or GSK regarding IV relenza.
GSK website search on relenza = 132 hits
Roche website search on tamifu = 189 PAGES OF HITS ~1886 hits
Mal
government orders intravenous relenza, page-8
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)